tbuckley/cabot-search huggingface dataset:
Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Authors: Arndt Vogel, Stefan Kasper, Wilko Weichert, Michael Bitzer, Andreas Block, Hanno Riess, Henning Schulze-Bergkamen, Markus H. Moehler, Kirsten Elisabeth Merx, Volker Endris, Elisabeth Schnoy, Jens T. Siveke, Patrick Michl, Dirk Waldschmidt, Jan Kuhlmann, Michael Geissler, Christoph Kahl, Stefan Kubicka
Journal: Journal of Clinical Oncology (2015)

4082 Background: Biliary tract cancer encompasses a group of genetically heterogeneous tumors. Panitumumab is a human EGFR inhibitor and has shown anti-tumor activity in RAS WT colorectal cancer. Methods: Pts with advanced KRAS wild type biliary tract or gallbladder adenocarcinoma were 2:1 randomized to receive Cis (25mg/m2) followed by Gem (1000mg/m2) on days 1 and 8 of a 21-day cycle, plus Panitumumab (6mg/kg) in arm A until disease progression. Primary endpoint was the progression-free survival rate at 6 months. For genetic profiling, massive parallel multigene sequencing was done by using a custom designed cholangiocarcioma multigene panel on an IonTorrent Proton. Mutations (21 genes) as well as amplifications and deletions (19 genes) were identified by panel tailored bioinformatic algorithms. Results: 93 pts were enrolled (63 per arm A and 30 arm B). Pts characteristics (panitumumab vs. control): median age 61.5 vs. 58.5 years; 59% vs. 50% male; intrahepatic, extrahepatic, gall bladder (%): 63, 16, 17 vs. 71, 11, 11; ECOG PS 0, 1, 2 (%): 64, 33, 2 vs. 45, 55; prior resection (%): 46 both arms. The most common grade 3-4 non-haematological adverse event (AE) was skin toxicity (39% vs 0%). Distribution of other grade 3-4 haematological and non-haematological AEs were not significantly different between both arms. 6-months PFS rate was not significantly different (55% vs 73%), mPFS was 6.7 vs. 8.2 mo, HR (95% CI, Gem/Cis ref.): 0.73 (0.43 – 1.24), p = 0.24; mOS was 12.8 vs. 21.4 mo, HR (95% CI, Gem/Cis ref.): 0.74 (0.39 – 1.4), p = 0.35; response rate (in evaluable pts): panitumumab (28/63 [45%] vs. control 11/28 [39%]. The most frequent genetic variations were detectable in p53 (34%), IDH1/2 (19%) and SMAD4 (11%) with up to 9 events per patient. The prognostic and predictive role of the variants is currently under investigation and will be presented. Conclusions: Panitumumab in combination with chemotherapy does not improve response rate, PFS and OS in patients with advanced bilary tract cancer. Further investigations of chemotherapy in combination with anti-EGFR antibodies are not warranted. Clinical trial information: NCT01320254.
Hunt for new health secretary is over as Jeremy stays in post
Authors: Nigel Hawkes
Journal: BMJ (2016)

Jeremy Hunt will remain health secretary for England despite a flurry of rumours that he would be sacked or at best transferred to another position.

His reappointment is seen at Westminster as a strong signal of support for Hunt’s long running disagreement with junior doctors over a new contract. Whatever his personal wishes may have been, the new UK prime minister, Theresa May, recognised that moving him would signal a lack of conviction in the dispute and embolden fresh industrial action by doctors who voted against a deal struck between Hunt and the BMA.

“Reports of my death have been greatly exaggerated,” tweeted Hunt after his reappointment. “Thrilled to be back in the best job in government.”

On the morning of Thursday 14 July Hunt had undergone death by Twitter, as a series of tweeters, …
Water exchange versus carbon dioxide insufflation in unsedated colonoscopy: less is more
Authors: Sauid Ishaq, Benjamin Disney, Sharan Shetty, Arun Kurup
Journal: Endoscopy (2015)

We congratulate Garborg et al. [1] for their recent multicenter, randomized, controlled study comparing water exchange with carbon dioxide (CO2) insufflation in unsedated colonoscopy. The primary end point of the study was the proportion of patients reporting moderate or severe pain at discharge. Regrettably, the study was not able to establish a statistically significant outcome with regard to the primary end point. We would like to raise the following points about the study.
Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload
Authors: David Ivars, Rosa Collado, Carmen Alguero, M Carmen Tormos, Laura Diaz, Jose Luis Garcia-Gimenez, Beatriz Arrizabalaga, Mayte Orero, Pedro Perez, Magdalena Sanchez, M Angeles Ruiz, Nuria Yagüe, Reyes Sancho-Tello, Ana Regadera, Mar Tormo, Mercedes Egea, Elena Vidal, J Enrique O'Connor, Guillermo T Saez, Felix Carbonell
Journal: Blood (2012)
B형간염 치료의 업데이트 : 새로운 항바이러스 요법
Authors: 황성규
Journal: Clinical and Molecular Hepatology (2006)

인터페론 제제와 함께 라미부딘(lamivudine, zeffix)과 아데포비어(adefovir dipivoxil, 이하 아데포비어)가 항바이러스제로 개발되어 만성 B형간염 환자의 치료에 사용되고 있다. 최근 보다 강력하고, 부작용이 적으며, 내성바이러스 출현이 낮은 여러 약제들이 개발 중에 있다. 강력한 항바이러스제의 사용이 가능해졌을 뿐 아니라, HBV (hepatitis B virus) 역동학(kinetics)이 밝혀졌다. 또한 분자생물학적 발전으로 B형간염 진단 및 치료를 추적하는데 HBV DNA의 검출이 300 copies/mL까지 가능해졌다. 이제 여러 종류의 새로운 항바이러스제가 등장하여 항바이러스 선택의 폭이 넓어졌으므로, HBV에 대한 최신 정보를 근거로 만성 B형간염치료에 대한 효율적인 전략을 수립하여야 한다. 특히 약제의 특성과 개개인 환자의 특성을 고려한 맞춤형 치료를 통해 장기간 항바이러스 요법에 필연적으로 나타나는 내성 바이러스 출현을 최소화하면서 항바이러스 효과를 극대화하여야 한다. 최근 임상에 도입되었거나 임상시험 진행 중으로 임상에 도입될 것으로 예상할 수 있는 약제와 함께 다양해진 HBV 치료전략을 기술하고자 한다.
In Utero Is Superior to Ex Utero Cord Blood Collection.
Authors: Elizabeth J. Shpall, Safa Karandish, Tara Sadeghi, Chitra Hosing, Christopher J. Garcia, Michael T. Cherry, Julia A. Walker, Corliss R. Denman, Rima M. Saliba, Richard E. Champlin, Marcelo Fernandez-Viña, Pedro Cano, John D. McMannis
Journal: Blood (2006)
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer
Authors: Brenda F. Kurland, Lanell M. Peterson, Jean H. Lee, Erin K. Schubert, Erin R. Currin, Jeanne M. Link, Kenneth A. Krohn, David A. Mankoff, Hannah M. Linden
Journal: Clinical Cancer Research (2016)

Abstract Purpose: 18F-fluoroestradiol (FES) PET scans measure regional estrogen binding, and 18F-fluorodeoxyglucose (FDG) PET measures tumor glycolytic activity. We examined quantitative and qualitative imaging biomarkers of progression-free survival (PFS) in breast cancer patients receiving endocrine therapy. Experimental Design: Ninety patients with breast cancer from an estrogen receptor–positive (ER+), HER2− primary tumor underwent FES PET and FDG PET scans prior to endocrine therapy (63% aromatase inhibitor, 22% aromatase inhibitor and fulvestrant, 15% other). Eighty-four had evaluable data for PFS prediction. Results: Recursive partitioning with 5-fold internal cross-validation used both FES PET and FDG PET measures to classify patients into three distinct response groups. FDG PET identified 24 patients (29%) with low FDG uptake, suggesting indolent tumors. These patients had a median PFS of 26.1 months (95% confidence interval, 11.2–49.7). Of patients with more FDG-avid tumors, 50 (59%) had high average FES uptake, and 10 (12%) had low average FES uptake. These groups had median PFS of 7.9 (5.6–11.8) and 3.3 months (1.4–not evaluable), respectively. Patient and tumor features did not replace or improve the PET measures' prediction of PFS. Prespecified endocrine resistance classifiers identified in smaller cohorts did not individually predict PFS. Conclusions: A wide range of therapy regimens are available for treatment of ER+ metastatic breast cancer, but no guidelines are established for sequencing these therapies. FDG PET and FES PET may help guide the timing of endocrine therapy and selection of targeted and/or cytotoxic chemotherapy. A multicenter trial is ongoing for external validation. Clin Cancer Res; 23(2); 407–15. ©2016 AACR.
Case 34-1981
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, Richard A. Norton, W. Stephen Black-Schaffer
Journal: New England Journal of Medicine (1981)

Presentation of CaseA 51-year-old woman was admitted to the hospital because of swelling and pain in the left knee.She was well until three years earlier, when both wrists became stiff; indomethacin gave no benefit, and the symptoms resolved spontaneously within four months. Ten weeks before admission swelling and pain in the left knee occurred abruptly, without trauma. X-ray films of the knee were normal. Microscopical examination of an aspirated specimen of synovial fluid showed a white-cell count of 5400; the glucose was 58 mg per 100 ml (3.2 mmol per liter). Local heat was administered, without benefit. Two . . .
C0818, a novel curcumin derivative, interacts with Hsp90 and inhibits Hsp90 ATPase activity
Authors: Yingjuan Fan, Yang Liu, Lianru Zhang, Fang Cai, Liping Zhu, Jianhua Xu
Journal: Acta Pharmaceutica Sinica B (2016)

The aims of the present study were to estimate the affinity between 3,5-(E)-bis(3-methoxy-4-hydroxybenzal)-4-piperidinone hydrochloride (C0818) and heat shock protein 90 (Hsp90) and to investigate the inhibitory effects of this compound on Hsp90 ATPase activity. Fluorescence spectroscopy was used to examine the affinity between varying concentrations of C0818 and Hsp90, N-Hsp90, M-Hsp90 and C-Hsp90. Fluorescence intensities were recorded in the range of 290-510 nm at 293, 303 and 310 K, respectively. A colorimetric assay for inorganic phosphate (based on the formation of a phosphomolybdate complex and the subsequent reaction with malachite green) were used to examine the inhibitory effects of C0818 on Hsp90 ATPase activity. The equilibrium dissociation constant KD value of C0818 was found to be 23.412±0.943 μmol/L. The interaction between C0818 and Hsp90 was driven mainly by electrostatic interactions. C0818 showed the strongest affinity with C-Hsp90. These results conclusively demonstrate the inhibitory activity of C0818 on the activity of Hsp90 ATPase.
Label-free CEST MRI Detection of Citicoline-Liposome Drug Delivery in Ischemic Stroke
Authors: Huanling Liu, Anna Jablonska, Yuguo Li, Suyi Cao, Dexiang Liu, Hanwei Chen, Peter CM Van Zijl, Jeff W.M. Bulte, Miroslaw Janowski, Piotr Walczak, Guanshu Liu
Journal: Theranostics (2016)

Citicoline (CDPC) is a natural supplement with well-documented neuroprotective effects in the treatment of neurodegenerative diseases. In the present study, we sought to exploit citicoline as a theranostic agent with its inherent chemical exchange saturation transfer (CEST) MRI signal, which can be directly used as an MRI guidance in the citicoline drug delivery. Our in vitro CEST MRI results showed citicoline has two inherent CEST signals at +1 and +2 ppm, attributed to exchangeable hydroxyl and amine protons, respectively. To facilitate the targeted drug delivery of citicoline to ischemic regions, we prepared liposomes encapsulating citicoline (CDPC-lipo) and characterized the particle properties and CEST MRI properties. The in vivo CEST MRI detection of liposomal citicoline was then examined in a rat brain model of unilateral transient ischemia induced by a two-hour middle cerebral artery occlusion. The results showed that the delivery of CPDC-lipo to the brain ischemic areas could be monitored and quantified by CEST MRI. When administered intra-arterially, CDPC-lipo clearly demonstrated a detectable CEST MRI contrast at 2 ppm. CEST MRI revealed that liposomes preferentially accumulated in the areas of ischemia with a disrupted blood-brain-barrier. We furthermore used CEST MRI to detect the improvement in drug delivery using CDPC-lipo targeted against vascular cell adhesion molecule (VCAM)-1 in the same animal model. The MRI findings were validated using fluorescence microscopy. Hence, liposomal citicoline represents a prototype theranostic system, where the therapeutic agent can be detected directly by CEST MRI in a label-free fashion.
Endocrinology of Childhood
Authors: E Thamdrup
Journal: BMJ (1944)

The article illustrates the special problems of endocrinology in childhood, where disturbances of growth and development may be explained by disorders of the endocrine organs. To-day, as a result of early diagnosis and effective treatment the understanding of the spontaneous course of some classical endocrine disorders in children is known essentially from historical descriptions. This article also describes the historical development of childhood endocrinology in Denmark.
High throughput in vitro combination sensitivity screen in hematologic malignancies with the phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib.
Authors: Kerrie Faia, Kerry White, Jennifer Proctor, Paula Andrade, Melissa Pink, Richard Rickles, Jill Grenier, Erwin Boghaert, Andrew James Souers, Joel Leverson, Vito J. Palombella, Karen McGovern, Jeffrey Lorne Kutok
Journal: Journal of Clinical Oncology (2015)

8559 Background: Signaling via PI3K-δ and PI3K-γ has distinct and complementary effects on the tumor cell/ tumor microenvironment in hematologic malignancies (HM). Duvelisib (IPI-145) is an orally active inhibitor of the PI3K-δ and PI3K-γ isoforms in clinical development in HM. To gain mechanistic insights into the cellular response to duvelisib and identify novel pairings for duvelisib in HM, a high-throughput in vitro combination screen was conducted. Methods: Duvelisib was evaluated alone and in combination with 35 compounds comprising a diverse panel of standard-of-care agents and emerging drugs in development for HM. These compounds were tested in 20 cell lines including diffuse large B-cell (DLBCL), follicular, T-cell, and mantle cell lymphomas, and multiple myeloma. Growth inhibition (GI) was measured by ATPLite (Perkin Elmer) in a 6x6 or 9x9 dose combination matrix. Results: Single agent activity was seen in 14 cell lines treated with duvelisib, with a median GI50 of 0.59 µM. A scalar measure of the strength of synergistic drug interactions (Synergy Score) was devised and filtering on scores exceeding the mean self-cross plus twice the standard deviation revealed a synergy hit rate of 19.3% across the matrix of drug combinations and cell lines. Synergy was most prominent in DLBCL and follicular lymphoma cell lines and seen with approved and emerging drugs used to treat HM, including, but not limited to, dexamethasone, inhibitors of the B-cell receptor signaling pathway, such as ibrutinib, and the BCL-2 inhibitor venetoclax (ABT-199). In select cell line GI studies and in vivo DoHH2 lymphoma murine xenograft models, the combination of selective PI3K-δ and PI3K-γ inhibitors showed enhanced effects compared to either inhibitor alone. Combination effects with select drugs and duvelisib were also seen in DoHH2 murine xenografts. Conclusions: These studies support enhanced activity of combined PI3K-δ and PI3K-γ inhibition in lymphoma models and identified synergistic pairings with the PI3K-δ and PI3K-γ inhibitor, duvelisib. These results provide a rationale for exploring the combination of duvelisib and other therapeutic agents in clinical studies.
Abstract 9593: Effects of Atorvastatin and Rosuvastatin on Renal Function: A Meta-analysis
Authors: Gianluigi Savarese, Francesca Musella, Massimo Volpe, Francesco Paneni, Pasquale Perrone-Filardi
Journal: Circulation (2012)

Objective: To compare the effects of Atorvastatin (A) and Rosuvastatin (R) on glomerular filtration rate (GFR) and new onset proteinuria in patients at high cardiovascular risk. Methods: Randomized trials on A or R treatments reporting clinical end-points were included in the meta-analysis. Influence of treatments on GFR and new onset proteinuria was assessed. Results: 23 trials enrolling 29,147 participants were included. A significant reduction in GFR was detected in placebo-treated compared to statin-treated patients (standard mean difference [SMD]:0.056, 95% confidence interval [CI]:0.028 to 0.083, p&lt;0.01). In particular, a significant reduction in GFR was detected in placebo compared to either R-treated (SMD:0.052, CI:0.022 to 0.081, p=0.001) or A-treated patients (SMD:0.084, CI:0.008 to 0.161, p=0.031). No significant difference in GFR was detected in 5 head-to-head studies comparing A to R (SMD: 0.043, CI:-0.041 to 0.126, p=0.319). In 9 studies comparing A to R, R treatment significantly increased the risk of proteinuria when compared to A (odds ratio [OR]:0.656, CI:0.440 to 0.977, p=0.038, heterogeneity p=0.026), but this effect was no longer significant when studies using highest therapeutic doses of R (40 mg/daily) were excluded from analysis, abolishing significant heterogeneity (OR:1.505, CI:0.827 to 2.739, p=0.181). Additionally, when trials comparing highest doses of A (80 mg/daily) and R (40 mg/daily) were analyzed, both A 80 mg and R 40 mg reduced GFR; but GFR tended to be significantly less reduced by A compared to R (SMD: 0.109, CI: -0.001 to 0.220, p=0.051). Finally in 7 trials enrolling only patients with chronic kidney disease (but not on dialysis), statin treatment (by either A or R) led to significant improvement in GFR compared to placebo (SMD:0.213, CI:0.043 to 0.382, p&lt;0.01). However, GFR was improved by A (SMD:0.246, CI:0.024 to 0.468, p=0.030), but it was not significantly changed by R treatment (SMD: 0.166, CI: -0.097 to 0.429, p=0.216). Conclusions: A and R show similar reno-protective effects in patients at high cardiovascular risk, with comparable rates of new onset proteinuria when commonly used doses are considered. In patients with chronic kidney disease, no further deterioration of GFR is observed.
Binding of Thyroxine to Serum Proteins
Authors: C S HOLLANDER, B H LATIMER, T E PROUT, D H LOCKWOOD, S P ASPER
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Much to learn about teaching: Reconciling form, function, phylogeny, and development
Authors: Michelle Ann Kline
Journal: Behavioral and Brain Sciences (2015)

Abstract The collection of commentaries expands an already extensive field of research on teaching, and contributes new questions, techniques, and strengths to the evolutionary approach proposed in the target article. In my response, I show how reconciling multiple levels of explanation – mechanistic, ontogenetic, phylogenetic, and functional – enables researchers to build a more integrated, interdisciplinary approach to the study of teaching in humans and other animals.
Citizens’ juries could help to guide screening policy
Authors: Cinzia Colombo, Paola Mosconi
Journal: BMJ (2016)

The article by Johansson and colleagues discusses informed choice in the context of the medicalisation of society, highlighting the common beliefs that “more is better” and “prevention is better than cure,” as well as the potential harm from information about a disease when people are asymptomatic, such as in screenings.1 …
Signs and symptoms as predictors of outcome: a report from the International Pilot Study of Schizophrenia
Authors: W T Carpenter, J J Bartko, J S Strauss, A B Hawk
Journal: American Journal of Psychiatry (1978)

The prognostic significance of signs and symptoms taken individually rather than in diagnostic clusters was investigated in 61 schizophrenic patients seen at 5-year follow-up in the Washington Center of the International Pilot Study of Schizophrenia. Best and worst outcome patients (Ns = 20) were selected on the basis of total outcome score from a reliable 9-item schedule; 21 middle-outcome patients were excluded. Data from these two groups were analyzed to determine which signs and symptoms assessed 5 years previously were associated with outcome. Only restricted affect predicted poor outcome: depression, anxiety, and nuclear symptoms of schizophrenia were not significant predictors. The findings are discussed within the conceptual framework of productive and defect symptoms.
Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group.
Authors: Lillian Sung, Richard Aplenc, Todd A. Alonzo, Robert B. Gerbing, Soheil Meshinchi, Laura Burden, Susana C. Raimondi, Betsy A. Hirsch, Samir Kahwash, Amy Heerema-McKenney, Laura Winter, Kathleen Glick, Patti Byron, Tanya Wallas, Franklin O. Smith, Alan S. Gamis
Journal: Blood (2010)
B형 간염 바이러스 내성과 대책 : YMDD mutant의 발생현황과 임상적 특성
Authors: 조몽
Journal: Clinical and Molecular Hepatology (2003)

배경/목적: 장투과성의 증가는 알코올성 간질환의 발병기전과 간경변증 환자의 균혈증과 자발성 세균성 복막염과 같은 세균감염의 발병 유발요인 중에 하나로 제시되고 있다. 하지만 간질환에서의 장투과성의 변화와 임상양상과의 관련성은 다양한 결과들이 보고 되고 있다. 본 연구에서는 바이러스성 및 알코올 간질환에서 장투과성의 변화 및 임상양상과의 연관성을 조사하였다. 대상과 방법: 건강대조군 18명, 알코올성 간염 17명, 알코올성 간경변증 24명, 만성 바이러스성 간염 14명, 바이러스성 간경변증 32명을 대상으로 장투과성검사를 실시하였으며 질환별, 알코올 섭취량, 흡연량, 문액압항진, 간성뇌증의 발생, Child-Purgh 분류, 간기능검사 수치 등의 임상양상과 연관성을 비교하였다. 장투과성 검사는 51Cr-EDTA (51Cr-ethylenediaminetetraacetic acid)을 이용하여 24시간 소변에서의 회수율로 측정하였다. 결과: 장투과성은 만성 바이러스성 간염(2.05±0.57%)에서 건강대조군(1.99±0.53%)보다 차이가 없었으나 바이러스성 간경변증(3.15±1.39%, p＜0.01)과 알코올성 간염(5.62±2.80%, p＜0.001) 및 알코올성 간경변증(5.29±2.48%, p＜0.001)에서 증가하는 양상을 보이며, 바이러스성 간경변증보다 알코올성 간질환에서 의미있게 높은 수치를 나타내었다(p＜0.05). 알코올성 간질환에서는 알코올성 간염과 간경변증사이에는 차이가 없었으며 일일 알코올 섭취량과 장투과성의 연관성은 관찰되지 않았다. 간경변증 환자에서 문액압 항진, 간성 뇌증의 발생, 간기능 검사, 흡연량, Child-Purgh 분류 등의 임상양상과 관련성이 없었다. 결론: 간질환 환자에서 장투과성의 증가는 바이러스성 간경변증과 알코올성 간질환에서 관찰되며, 알코올성 간질환에서 바이러스성 간질환보다 높은 수치를 보이나 알코올성 간질환 간에는 차이가 없었다.
Serum Lactic Dehydrogenase in Cancer Patients&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Hill, J. H.
Journal: JNCI Journal of the National Cancer Institute (1957)

Journal Article Serum Lactic Dehydrogenase in Cancer Patients Get access J. H. Hill, M.D. J. H. Hill, M.D. Department of Pathology and Oncology, University of Kansas Medical School, Kansas City, Kansas Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 18, Issue 2, February 1957, Pages 307–313, https://doi.org/10.1093/jnci/18.2.307 Published: 01 February 1957 Article history Received: 29 August 1956 Published: 01 February 1957